<DOC>
	<DOCNO>NCT02503202</DOCNO>
	<brief_summary>The study evaluate safety immunogenicity 3 consistency lot high-dose lot rVSV-ZEBOV-GP ( V920 Ebola Vaccine ) healthy adult . The primary purpose study demonstrate consistency immune response participant receive 3 separate lot V920 ( release dose ) 28 day postvaccination . A subset participant representative treatment group continue 24 month postvaccination extension study evaluation safety , durability immune response . Safety vaccine match placebo evaluate 6 month postvaccination participant 24 month postvaccination participant continue study extension .</brief_summary>
	<brief_title>Evaluation Safety Immunogenicity Three Consistency Lots High-Dose Lot rVSV-ZEBOV-GP ( V920 Ebola Vaccine ) Healthy Adults ( V920-012 )</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Not reproductive potential , reproductive potential agree avoid become pregnant impregnating partner 2 month follow study vaccination . Is currently participate participate interventional clinical trial investigational compound device within 90 day participation trial . Has previously randomize another clinical trial receive V920 Ebola vaccine . Has expose Ebola virus time prior study entry . Is pregnant breastfeed plan conceive within 2 month follow study vaccination . Has direct household exposure pregnant lactate woman time participation trial . Has know suspect impairment immunological function ( e.g. , HIV positive ) . Has direct household exposure person know suspected impairment immunological function ( e.g. , HIV positive ) . Has clinically significant history intravenous ( IV ) drug abuse within 12 month prior study entry . Has know allergy/sensitivity contraindication investigational product ( ) its/their excipients ( e.g. , albumin ) . Has history malignancy &lt; =5 year prior study entry except adequately treat basal cell squamous cell skin cancer situ cervical cancer . Is immediate family member ( e.g. , spouse , parent/legal guardian , sibling child ) investigational site sponsor staff directly involve trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>